Search
CMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Zinc glycinate
go.drugbank.com/drugs/DB14493InvestigationalGlycoprotein marker of gastrointestinal cancer.
Mixtures: FeRiva 21 7, FeRiva 21-7 28-DayVapitadine
go.drugbank.com/drugs/DB05738ExperimentalAn advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
beta-Alanine
go.drugbank.com/drugs/DB03107InvestigationalSince neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID.
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
International brands: M-Trex3,4-Methylenedioxy-N-isopropylamphetamine
go.drugbank.com/drugs/DB06112ExperimentalMDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
Pemivibart
go.drugbank.com/drugs/DB18720InvestigationalPemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COV...
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation
Leptin
go.drugbank.com/drugs/DB05098InvestigationalThese people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin.
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.